FBXO2 and ovarian serous tumor: We investigated whether galectin-3 expression of these three commercially available ovarian cell lines (Figure 1B) is comparable to the expression of ovarian cell lines established out of primary serous ovarian tumors in our laboratory (KI-OCp1, 11 and 012, stage IIIc) and freshly isolated serous ovarian tumor cells (KI-OCp79, 88 and 91, stage III) (Figure 1C).